Hims stock falls after lawmakers propose GLP-1 compounding restrictions

Investing.com -- Hims Hers Health Inc (NYSE: HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

TN must share expiration date of drugs used in past executions: judge

The state has opposed the court order to share the expiration dates because they say the dates could reveal the supplier of the drugs, jeopardizing the state's ability to obtain them in the future, ...
The Manila Times

SuspendIt® Is Now a USP Verified Excipient

PCCA Adds to Its Family of USP Verified Excipient Compounding Bases ...
InkFreeNews.com

Yakym, Carson Introduce Bill To Protect Patients From Unsafe Compounded Drugs

On Dec. 10, U.S. Rep. Rudy Yakym, Republican of Indiana's 2nd District, and U.S. Rep. André Carson, Democrat of Indiana's 7th ...

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
pharmaphorum

Thermo Fisher Scientific on the value of an integrated approach to drug development

To address this, Thermo Fisher Scientific now offers Accelerator Drug Development: a suite of integrated services combining CDMO and CRO capabilities to streamline the drug development journey, from ...